The HDAC inhibitors may be a good option, because in myeloid malignancies, failure of normal differentiation often results from an inability to transcribe genes that encode proteins that either mediate or define the mature phenotype (Batty et al, 2009). The gene discussed is HDAC9; the disease is myeloid neoplasm.